Cargando…

Prescription of Silexan Is Associated with Less Frequent General Practitioner Repeat Consultations Due to Disturbed Sleep Compared to Benzodiazepine Receptor Agonists: A Retrospective Database Analysis

The aim of the present study was to analyze the association between the prescription of Silexan and the recurrence of general practitioner (GP) repeat consultations because of disturbed sleep versus benzodiazepine receptor agonists including zolpidem, zopiclone, and zaleplon (Z-drugs). This retrospe...

Descripción completa

Detalles Bibliográficos
Autores principales: Krüger, Tillmann, Becker, Eva-Maria, Kostev, Karel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9819079/
https://www.ncbi.nlm.nih.gov/pubmed/36611537
http://dx.doi.org/10.3390/healthcare11010077
_version_ 1784865142851239936
author Krüger, Tillmann
Becker, Eva-Maria
Kostev, Karel
author_facet Krüger, Tillmann
Becker, Eva-Maria
Kostev, Karel
author_sort Krüger, Tillmann
collection PubMed
description The aim of the present study was to analyze the association between the prescription of Silexan and the recurrence of general practitioner (GP) repeat consultations because of disturbed sleep versus benzodiazepine receptor agonists including zolpidem, zopiclone, and zaleplon (Z-drugs). This retrospective cohort study was based on data from the IQVIA Disease Analyzer (DA) database. The study included adult patients treated by 1284 GPs in Germany with a documented sleep disorder and their first prescription of Silexan or Z-drug (prescription between January 2010 and October 2020). The recurrence of seeking medical advice because of sleep disorders in the 15–365 days after the first prescription was evaluated. Multivariate regression models were used, adjusted for age, sex, insurance status, and defined co-diagnoses. Data were available for 95,320 (Silexan: 5204; Z-Drug: 90,526) patients. In total, 15.6% of the Silexan patients and 28.6% of the Z-drug patients had a further documented GP consultation because of a sleep disorder. Silexan prescription was associated with significantly lower odds of recurrent sleep disorder diagnosis in the 15–365 days after the index date (Odds Ratio (OR): 0.56; 95% confidence intervals (CI): 0.51–0.60), although mental burden levels appeared higher in this group. Our study shows that the prescription of Silexan to adult patients consulting GPs for disturbed sleep results in less frequent repeat consultations than Z-drugs. This may support Silexan’s role as an efficacious, self-enabling, well-tolerated, and sustained treatment option. Because Silexan is a proven anxiolytic, its impact in improving undiagnosed anxiety disorders may have had a lasting effect for certain patients.
format Online
Article
Text
id pubmed-9819079
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98190792023-01-07 Prescription of Silexan Is Associated with Less Frequent General Practitioner Repeat Consultations Due to Disturbed Sleep Compared to Benzodiazepine Receptor Agonists: A Retrospective Database Analysis Krüger, Tillmann Becker, Eva-Maria Kostev, Karel Healthcare (Basel) Article The aim of the present study was to analyze the association between the prescription of Silexan and the recurrence of general practitioner (GP) repeat consultations because of disturbed sleep versus benzodiazepine receptor agonists including zolpidem, zopiclone, and zaleplon (Z-drugs). This retrospective cohort study was based on data from the IQVIA Disease Analyzer (DA) database. The study included adult patients treated by 1284 GPs in Germany with a documented sleep disorder and their first prescription of Silexan or Z-drug (prescription between January 2010 and October 2020). The recurrence of seeking medical advice because of sleep disorders in the 15–365 days after the first prescription was evaluated. Multivariate regression models were used, adjusted for age, sex, insurance status, and defined co-diagnoses. Data were available for 95,320 (Silexan: 5204; Z-Drug: 90,526) patients. In total, 15.6% of the Silexan patients and 28.6% of the Z-drug patients had a further documented GP consultation because of a sleep disorder. Silexan prescription was associated with significantly lower odds of recurrent sleep disorder diagnosis in the 15–365 days after the index date (Odds Ratio (OR): 0.56; 95% confidence intervals (CI): 0.51–0.60), although mental burden levels appeared higher in this group. Our study shows that the prescription of Silexan to adult patients consulting GPs for disturbed sleep results in less frequent repeat consultations than Z-drugs. This may support Silexan’s role as an efficacious, self-enabling, well-tolerated, and sustained treatment option. Because Silexan is a proven anxiolytic, its impact in improving undiagnosed anxiety disorders may have had a lasting effect for certain patients. MDPI 2022-12-27 /pmc/articles/PMC9819079/ /pubmed/36611537 http://dx.doi.org/10.3390/healthcare11010077 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Krüger, Tillmann
Becker, Eva-Maria
Kostev, Karel
Prescription of Silexan Is Associated with Less Frequent General Practitioner Repeat Consultations Due to Disturbed Sleep Compared to Benzodiazepine Receptor Agonists: A Retrospective Database Analysis
title Prescription of Silexan Is Associated with Less Frequent General Practitioner Repeat Consultations Due to Disturbed Sleep Compared to Benzodiazepine Receptor Agonists: A Retrospective Database Analysis
title_full Prescription of Silexan Is Associated with Less Frequent General Practitioner Repeat Consultations Due to Disturbed Sleep Compared to Benzodiazepine Receptor Agonists: A Retrospective Database Analysis
title_fullStr Prescription of Silexan Is Associated with Less Frequent General Practitioner Repeat Consultations Due to Disturbed Sleep Compared to Benzodiazepine Receptor Agonists: A Retrospective Database Analysis
title_full_unstemmed Prescription of Silexan Is Associated with Less Frequent General Practitioner Repeat Consultations Due to Disturbed Sleep Compared to Benzodiazepine Receptor Agonists: A Retrospective Database Analysis
title_short Prescription of Silexan Is Associated with Less Frequent General Practitioner Repeat Consultations Due to Disturbed Sleep Compared to Benzodiazepine Receptor Agonists: A Retrospective Database Analysis
title_sort prescription of silexan is associated with less frequent general practitioner repeat consultations due to disturbed sleep compared to benzodiazepine receptor agonists: a retrospective database analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9819079/
https://www.ncbi.nlm.nih.gov/pubmed/36611537
http://dx.doi.org/10.3390/healthcare11010077
work_keys_str_mv AT krugertillmann prescriptionofsilexanisassociatedwithlessfrequentgeneralpractitionerrepeatconsultationsduetodisturbedsleepcomparedtobenzodiazepinereceptoragonistsaretrospectivedatabaseanalysis
AT beckerevamaria prescriptionofsilexanisassociatedwithlessfrequentgeneralpractitionerrepeatconsultationsduetodisturbedsleepcomparedtobenzodiazepinereceptoragonistsaretrospectivedatabaseanalysis
AT kostevkarel prescriptionofsilexanisassociatedwithlessfrequentgeneralpractitionerrepeatconsultationsduetodisturbedsleepcomparedtobenzodiazepinereceptoragonistsaretrospectivedatabaseanalysis